Quick Answer
Anika Therapeutics, Inc. reported Stockholders Equity of $143.47 million for the year ending 2025.
- Anika Therapeutics, Inc. showed a decrease of -6.8% in Stockholders Equity from 2024 to 2025.
- This data is from Anika Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $156.57 million | Q2 2014: $162.39 million | Q3 2014: $169.70 million | Q1 2015: $181.82 million | Q2 2015: $190.57 million | Q3 2015: $199.75 million | Q1 2016: $195.37 million | Q2 2016: $204.42 million | Q3 2016: $214.54 million | Q1 2017: $230.03 million | Q2 2017: $244.14 million | Q3 2017: $253.29 million | Q1 2018: $263.77 million | Q2 2018: $246.60 million | Q3 2018: $255.27 million | Q1 2019: $269.07 million | Q2 2019: $250.95 million | Q3 2019: $281.68 million | Q1 2020: $293.69 million | Q2 2020: $288.44 million | Q3 2020: $284.45 million | Q1 2021: $276.66 million | Q2 2021: $286.80 million | Q3 2021: $290.06 million | Q1 2022: $285.79 million | Q2 2022: $286.15 million | Q3 2022: $284.94 million | Q1 2023: $277.59 million | Q2 2023: $274.02 million | Q3 2023: $270.49 million | Q1 2024: $208.54 million | Q2 2024: $210.34 million | Q3 2024: $179.86 million | Q1 2025: $148.40 million | Q2 2025: $147.67 million | Q3 2025: $146.81 million.
- Over the full 14 years of available data (2012 to 2025), Anika Therapeutics, Inc.'s Stockholders Equity has grown by 31.7%.
- Historical annual values: Fiscal year 2025: $143.47 million | Fiscal year 2024: $153.99 million | Fiscal year 2023: $212.27 million | Fiscal year 2022: $285.56 million | Fiscal year 2021: $287.09 million | Fiscal year 2020: $272.40 million | Fiscal year 2019: $288.38 million | Fiscal year 2018: $263.61 million | Fiscal year 2017: $263.49 million | Fiscal year 2016: $222.77 million | Fiscal year 2015: $210.85 million | Fiscal year 2014: $178.10 million | Fiscal year 2013: $135.64 million | Fiscal year 2012: $108.93 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: